In conclusion, osthole and imperatorin may represent new pharmacological tools for the treatment of osteoporosis.
Anti-VEGF agents may represent new therapeutic alternatives for children with advanced disease.
Thanks to their unique biological features, these compounds may represent new therapeutic tools for cardiovascular, neuromuscular and inflammatory diseases.
These small molecules may represent new classes of ER antagonists, and may have the potential to provide an alternative for the current anti-estrogen therapy.
Such alternatives photoinitiators systems may represent new perspectives for development of dental materials; therefore, more studies should be conducted to investigate the behavior and applicability of this initiation system, regarding biological, optical and physic-mechanical properties.
Nanomedicine approaches, especially by the use of nanoparticle-based compounds for the delivery of drugs, cancer diagnosis or therapeutics may represent new and modern ways in the near future anti-cancer therapies.
Significantly, these changes in miRNA expression and associated machinery may represent new targets for pharmaceutical development, and the identification of miRNA signatures in PBMCs suggest that miRNA biomarkers of schizophrenia may also provide the basis for new clinical diagnostics.
Finally, the essential role of autophagy for differentiation and pathogenicity of some pathogenic protists suggests that the proteins involved in this process may represent new targets for drug development.
The minor QTL (qph1-2 and qph9-1) mapped in our population has not been reported previously and may represent new genetic intervals linked to PH. Figure 4 Genome-wide scan in the F2 population and QTL trait mapping.
They constitute novel, effective antimicrobial peptides that are much shorter (and thus less expensive to produce) than the natural cathelicidins, and they may represent new templates for therapeutic drug development.
Pregnane glycosides are potent cytotoxic agents which may represent new leads in the development of anti-tumour drugs, particularly in the treatment of breast cancer, because of the structural similarity to estrogenic agonists.
